Adverse reactions were reported in 202 of 3,196 patients (6.3%) in post marketing observational study in Japan. The major adverse reactions were eye irritation in 30 patients (0.9%), eye discharge in 30 patients (0.9%), eye pain in 22 patients (0.7%), lacrimation increased in 20 patients (0.6%) and blepharitis in 19 patients (0.6%), etc.
If an adverse drug reaction is observed, appropriate measures including discontinuing administration should be taken. (See table.)
![](https://mpfshstrg.blob.core.windows.net/mpf-uat-common-resources/Images/monograph/table.gif)
Diquas-S: Incidence was calculated based on the clinical study results up to the approval of diquafosol ophthalmic solution 3% (multidose bottles containing preservative).
View ADR Monitoring Form